Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies

 Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Shots:

  • Merus to receive $40M up front, $20M as an equity investment, ~$540M as development & commercial milestones making it a total of $1.6B for three products, along with royalties, following the commercialization of therapies
  • Merus will lead discovery and early-stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development, and commercialization activities
  • The collaboration leverages Merus’ Biclonics platform along with the scientific & rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell redirecting bispecific Ab therapies

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bilaterals.org

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post